Direct comparison
Oncology vs Hematology: Key Differences
Oncology treats cancer; hematology treats blood and marrow disorders, benign and malignant. Compare scope, funders, trial networks, training and overlap.
Written and maintained by CASRAI Editorial Board
Last updated
Ask CASRAI · free to try
Ask about Oncology vs Hematology: Key Differences
Ask your first 2 questions free below. Subscribers get 150 a day for $29 a month.
An AI assistant specialized in research administration. It cites the sources behind every answer, labels web answers and says when it can't answer.
Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.
Works on this site and inside Claude, Cursor and the AI tools you already use.
Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays free to read, with no account and no card.
How do Oncology, Hematology compare side by side?
The table below compares Oncology, Hematology across 14 procurement-relevant dimensions, from definition through when to use which term.
Side-by-side comparison
| Dimension | Oncology | Hematology |
|---|---|---|
| Definition | The branch of medicine and biomedical science devoted to cancer: how it arises, how it is detected and classified, how it is treated, and how those treatments are tested. | The branch of medicine and biomedical science that studies blood, bone marrow and other blood-forming tissues, and the lymphatic and clotting systems that work with them, along with the diseases that affect them. |
| What organizes the field | A disease type. Cancer is defined by cells that grow uncontrollably and can spread, and it can occur in almost any tissue. | An organ system. Blood and the marrow that makes it are the unifying subject, whether the problem is too few cells, abnormal cells, clotting failure or uncontrolled growth. |
| Scope: solid tumors vs blood disorders | Mostly solid tumors, including carcinomas, sarcomas, melanoma and brain and spinal cord tumors, plus cancers of blood-forming tissue where they overlap with hematology. | Mostly blood and marrow disorders. Includes both non-malignant (benign) hematology and malignant hematology, so a large share of the field is not cancer. |
| Typical conditions | Breast, lung, colon and prostate cancers, sarcomas, melanoma, brain tumors, pediatric cancers and, at the overlap, leukemia, lymphoma and myeloma. | Anemias, sickle cell disease and thalassemia, bleeding disorders such as hemophilia, venous thromboembolism, bone marrow failure, platelet and white cell disorders, plus the blood cancers. |
| Key diagnostics (general terms) | Biopsy and pathology review, imaging for staging and response assessment, and tumor molecular and biomarker testing that can guide targeted treatment. | Complete blood count and blood smear review, coagulation testing, flow cytometry, bone marrow aspiration and biopsy, and genetic testing for inherited and malignant disorders. |
| Main treatment approaches (general terms) | Surgery, radiation and systemic drug therapy (chemotherapy, hormone therapy, targeted therapy, immunotherapy), usually coordinated by a multidisciplinary team. | Depends on the disorder: replacing or supplementing blood components, antithrombotic or clotting-factor therapy, drug treatment, stem cell transplantation, and cell and gene-based therapies. Blood cancers also use cancer-directed drug regimens. |
| Trial networks | Publicly funded cancer trials in the US and Canada run largely through the NCI National Clinical Trials Network, which includes the Alliance, ECOG-ACRIN, NRG Oncology, SWOG, the Children's Oncology Group and the Canadian Cancer Trials Group. | Non-malignant blood research uses disease-specific networks and registries, such as the Blood and Marrow Transplant Clinical Trials Network supported by NHLBI. Blood-cancer trials also run through the oncology networks. |
| Typical endpoints (general terms) | Tumor response on imaging, progression-free and overall survival, and other time-to-event measures. Surrogate and composite endpoints are common. | Varies by disease: blood counts and laboratory values, bleeding or clotting events, transfusion needs, and survival for blood cancers. Many diseases are rare, so registry-based designs and long follow-up are common. |
| Training path (US, general terms) | Medical school, then residency in internal medicine (medical oncology), surgery (surgical oncology) or radiation oncology, then fellowship for medical and surgical oncology. | Medical school, internal medicine or pediatrics residency, then fellowship. Many physicians train in a combined hematology-oncology pathway, and requirements vary by country, so check the relevant certifying body. |
| Main US research funders | The National Cancer Institute within NIH leads, supplemented by other federal programs, state programs, industry and charitable organizations. | NHLBI (non-neoplastic blood diseases, sickle cell disease, thrombosis, transfusion safety, transplantation) and NIDDK (blood cell biology, thalassemia, iron disorders) for non-malignant work; the NCI for leukemia, lymphoma and myeloma. Confirm the right institute with NIH program staff. |
| Professional societies and journals | American Society of Clinical Oncology (ASCO; Journal of Clinical Oncology) and the American Association for Cancer Research (AACR). | American Society of Hematology (ASH; the journal Blood), plus the International Society on Thrombosis and Haemostasis, the World Federation of Hemophilia and, for blood banking, AABB. |
| Career and workforce | Medical, surgical, radiation and pediatric oncologists, oncology nurses, medical physicists, plus PhD cancer biologists, biostatisticians and research staff at cancer centers and trial networks. | Hematologists, hematopathologists, transfusion medicine and blood bank specialists, coagulation and flow cytometry laboratory staff, and hematology researchers working with blood and marrow samples. |
| Overlap | Hematologic oncology treats leukemias, lymphomas and myeloma, often as a joint field with hematology. Stem cell transplantation is a major treatment for blood cancers. | Malignant hematology covers the same blood cancers, and hematopoietic stem cell transplantation and cellular therapy bridge the fields. Pediatric hematology is often combined with oncology in one subspecialty. |
| When to use which term | Use oncology for cancer in general or for solid tumors, and for treatment modalities such as radiation, surgery and systemic therapy for cancer. | Use hematology for disorders of blood cells, clotting, marrow and transfusion, including non-cancer conditions. Use hematology-oncology or hematologic oncology for blood cancers. |
Common questions
Common questions about Oncology vs Hematology
What is the main difference between oncology and hematology?
+
Oncology is defined by a disease type (cancer, in any tissue), while hematology is defined by an organ system (blood, bone marrow and clotting). That is why oncology is mostly about solid tumors and hematology includes many non-cancer conditions such as anemia, sickle cell disease and bleeding disorders.
Is a hematologist an oncologist?
+
Not necessarily. A hematologist may focus entirely on non-malignant blood disorders, such as clotting problems or anemia. Many physicians, however, train in a combined hematology-oncology pathway and treat both blood disorders and cancers. Requirements vary by country, so check the relevant certifying body for how a given title is earned.
Is leukemia treated by oncology or hematology?
+
Both. Leukemia, lymphoma and multiple myeloma are cancers of the blood and marrow, so they sit in the overlap: malignant hematology from one side and hematologic oncology from the other. Which specialist leads care depends on the practice and the patient, and a hematologist-oncologist often covers both. This page is educational and is not medical advice.
Is hematology only about blood cancer?
+
No. Hematology has a long-standing split between benign (non-malignant) and malignant work. Benign hematology covers anemias, hemoglobin disorders, bone marrow failure, bleeding and clotting disorders and platelet disorders. Malignant hematology, the blood cancers, is only one part of the field.
Do oncology and hematology have different research funders?
+
In the United States, largely yes. The National Cancer Institute leads cancer research funding and is the usual home for leukemia, lymphoma and myeloma, while the National Heart, Lung, and Blood Institute and the National Institute of Diabetes and Digestive and Kidney Diseases carry most non-malignant blood research. Assignments depend on the application, so confirm the right institute and funding announcement with NIH program staff.
How do oncology and hematology trials differ?
+
Publicly funded cancer trials commonly run through the NCI National Clinical Trials Network and often use imaging-based tumor response and survival endpoints. Many blood diseases are rare, so hematology research leans on registries, disease-specific networks, long follow-up and laboratory-based outcomes, while blood-cancer trials use the oncology networks and endpoints. The phase structure of trials is the same across both.
Where do radiation oncology and pathology fit?
+
Radiation oncology is a treatment specialty within oncology that uses ionizing radiation to destroy cancer cells. Pathology is not an oncology subspecialty as such, but cancer diagnosis and staging depend on it, and hematopathology plays the same role for blood and marrow disease. See the linked guides for each.
